Forte Biosciences Inc (FBRX) - Long-Term Debt to Capital Coefficient
Forte Biosciences, Inc. (FBRX) lacks revenue predictability, as the development of skin treatments is not profitable. The company is in a state of financial deficit, consuming capital to research drugs for autoimmune pathologies. The linear price action on the GURU.Markets chart is 0.00, while external risks and sanctions could disrupt component logistics and hinder the international certification of technologies.
%20Long-Term%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261101&filename=GURU_Markets_-_FBRX_-_Forte-Biosciences-Inc._-_Long-Term-Debt-to-Capital "FBRX: Forte Biosciences Long-Term Debt to Capital 07/04/2022 - 09/06/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for Forte Biosciences, Inc. (FBRX)
This ratio assesses financial stability by comparing long-term credit obligations to the market value of equity to determine the business's degree of leverage. By analyzing the trend of the long-term debt-to-equity ratio, an investor can see the balance between debt load and capitalization potential, which is critically important for Forte Biosciences, Inc. (FBRX) as it prepares for the commercialization of its unique drug FB-102 with significant pricing power.